טוען...
MEDU-47. PEROXIREDOXIN1 IS A THERAPEUTIC TARGET IN GROUP-3 MEDULLOBLASTOMAS
Group-3 Medulloblastomas (MBL) has the worst prognosis due to its resistance to radiation and chemotherapy with a 5-year survival of 30%. Thus, there is an urgent need to elucidate targets that can sensitize Group-3 tumors to conventional treatments. We identified PRDX1 as a candidate therapeutic ta...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475172/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.196 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|